Whitepaper: Oncology therapeutics discovery solutions
Streamline oncology therapeutic development with CST® recombinant monoclonal antibodies, ELISA & cellular assay kits, & custom products & services.
List view / Grid view
Streamline oncology therapeutic development with CST® recombinant monoclonal antibodies, ELISA & cellular assay kits, & custom products & services.
Drug discovery trends in 2023 will change the way we conduct science and result in entirely new, more efficient, and effective research paradigms. Through increased public-private partnerships, multidisciplinary collaboration and patient engagement in the drug discovery process, we will see new vaccines and therapies getting to the public faster and…
Advance your neurodegeneration research with our broad antibody portfolio, ready-to-use ELISA, and cellular kits to develop new efficacious therapies.
Discover how Catalent can help you achieve efficiencies and develop a robust, reproducible manufacturing plan for late-stage and commercial launch.
Development of novel rabbit monoclonal antibodies to characterise microglial activation states in murine models of Alzheimer’s disease.
Need some direction in choosing immune cell markers? Whether you are working with human cells or a mouse model, CST has you covered!
20 December 2022 | By Eurofins DiscoverX Corp.
In this webinar, we present an approach for building MOA-based, simple, ready-to-use GLP-1 and GLP-2 bioassays and discuss assay validation results from Eurofins BPT.
Read about the current state of the industry, challenges associated with potency assays and measuring product potency throughout the manufacturing process.
Understand how quality control assays are being implemented in monitoring the development of CAR-T cells using high-throughput technologies in this article.
Measure protein, DNA and RNA in FFPE tissue samples using rigorously IHC validated CST antibodies on the NanoString® nCounter® platform.
Discover everything pharmaceutical scientists need to know about solid form characterisation, starting with API selection.
Dr. Stokes, Associate Director Proteomics, discusses how proteomic studies can increase effectiveness, speed of target and biomarker identification.
Discover how Malvern Panalytical’s combination of analytical instrumentation and research services can take particle size analysis to the next level.
This Malvern Panalytical guide explores the use of Xray powder diffraction (XRPD) as a powerful tool to develop and improve pharmaceutical formulation.
Looking for solutions to resolve your unique challenges? We offer several customized products and services to move your discovery forward.